Literature DB >> 8822987

Tonic chemoreflex activation does not contribute to elevated muscle sympathetic nerve activity in heart failure.

P van de Borne1, R Oren, E A Anderson, A L Mark, V K Somers.   

Abstract

BACKGROUND: Sympathetic activation in heart failure may be due to an increase in sympathetic excitatory influences or to a decrease in inhibitory signals to the brain stem. Chemoreflex sensitivity may be increased in patients with heart failure. The present study tested the hypothesis that tonic activation of excitatory chemoreceptor afferents contributes to the elevated sympathetic activity in heart failure. METHODS AND
RESULTS: We recorded sympathetic nerve activity to muscle circulation from the peroneal nerve of 12 chronic heart failure patients while the patients were breathing room air and during deactivation of the chemoreceptors while the patients were breathing a 100% O2 gas mixture. All patients except 2 were in class III of the New York Heart Association functional classification. Left ventricular ejection fraction defined by radionuclide ventriculography was 24 +/- 2% (mean +/- SE). We also obtained measurements of resting sympathetic nerve activity in 9 healthy control subjects to document that sympathetic nerve activity was elevated in heart failure subjects. Resting sympathetic nerve activity was 59 +/- 5 bursts/min in heart failure patients versus 36 +/- 4 bursts/min in control subjects (P < .01). In heart failure patients, oxygen administration increased oxygen saturation from 94 +/- 0.9% to 99 +/- 0.3% (P < .0001). This increase in oxygen saturation did not affect resting muscle sympathetic nerve activity (798 +/- 122 U/min while patients breathed room air and 824 +/- 35 U/min during 100% O2 breathing) or blood pressure.
CONCLUSIONS: Increased efferent sympathetic activity to muscle circulation in patients with heart failure is not explained by tonic activation of excitatory chemoreflex afferents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8822987     DOI: 10.1161/01.cir.94.6.1325

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Cost-effectiveness of coronary interventions.

Authors:  D J Cohen; C A Sukin
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

2.  Should we be 'doping' the peripheral chemoreceptors?

Authors:  Jacqueline K Limberg; Michael J Joyner
Journal:  J Physiol       Date:  2014-03-15       Impact factor: 5.182

3.  Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers.

Authors:  Atul Pathak; Sonia Velez-Roa; Olivier Xhaët; Boutaina Najem; Philippe van de Borne
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 4.  Carotid body function in heart failure.

Authors:  Harold D Schultz; Yu Long Li
Journal:  Respir Physiol Neurobiol       Date:  2007-02-16       Impact factor: 1.931

Review 5.  Chemoreflex function in heart failure.

Authors:  H D Schultz; S Y Sun
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 6.  The control of adrenergic function in heart failure: therapeutic intervention.

Authors:  A L Clark; J G Cleland
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 7.  Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies.

Authors:  Kamila Lachowska; Marcin Gruchała; Krzysztof Narkiewicz; Dagmara Hering
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

Review 8.  Regulation of the renal sympathetic nerves in heart failure.

Authors:  Rohit Ramchandra; Carolyn J Barrett
Journal:  Front Physiol       Date:  2015-08-25       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.